Oxazole and thiazole compounds as beta-catenin modulators and uses thereof

A method for treating or ameliorating in a mammal a disease or condition that is causally related to the aberrant activity of the Wnt signaling pathway in vivo, wherein the disease or condition is a cancer, which method comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:

• wherein A is A1;
• A1 is
• x is 1;
• L1 is S, SO or SO2;
• m1 is 1, 2 or 3;
• n is 1, 2, 3, 4 or 5;
• each R1, R2a, R2b, R2c, and R2d is independently selected from hydrogen, halo, and substituted or unsubstituted C1-C6 alkyl;
• R3 is hydroxy, alkoxy, substituted or unsubstituted amino or cycloheteroalkyl;
• each R4 is independently selected from H, alkyl, substituted alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted or unsubstituted sulfonyl, substituted or unsubstituted sulfinyl, substituted or unsubstituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted dialkylamino, halo, heteroaryloxy, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkyl, hydroxy, nitro, and thiol;
• or a pharmaceutically acceptable salt, solvate or prodrug thereof;
• and stereoisomers, isotopic variants and tautomers thereof.